Academic Journal

Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer

التفاصيل البيبلوغرافية
العنوان: Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer
المؤلفون: Kosinova Veronika, Pavlu Hana, Coene Ilse, Navratilova Marie, Vasickova Petra, Lukesova Mirka, Foretova Lenka, Machackova Eva, Kuklova Jitka, Claes Kathleen
المصدر: BMC Cancer, Vol 8, Iss 1, p 140 (2008)
بيانات النشر: BMC, 2008.
سنة النشر: 2008
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Abstract Background The incidence of breast cancer has doubled over the past 20 years in the Czech Republic. Hereditary factors may be a cause of young onset, bilateral breast or ovarian cancer, and familial accumulation of the disease. BRCA1 and BRCA2 mutations account for an important fraction of hereditary breast and ovarian cancer cases. One thousand and ten unrelated high-risk probands with breast and/or ovarian cancer were analysed for the presence of a BRCA1 or BRCA2 gene mutation at the Masaryk Memorial Cancer Institute (Czech Republic) during 1999–2006. Methods The complete coding sequences and splice sites of both genes were screened, and the presence of large intragenic rearrangements in BRCA1 was verified. Putative splice-site variants were analysed at the cDNA level for their potential to alter mRNA splicing. Results In 294 unrelated families (29.1% of the 1,010 probands) pathogenic mutations were identified, with 44 different BRCA1 mutations and 41 different BRCA2 mutations being detected in 204 and 90 unrelated families, respectively. In total, three BRCA1 founder mutations (c.5266dupC; c.3700_3704del5; p.Cys61Gly) and two BRCA2 founder mutations (c.7913_7917del5; c.8537_8538del2) represent 52% of all detected mutations in Czech high-risk probands. Nine putative splice-site variants were evaluated at the cDNA level. Three splice-site variants in BRCA1 (c.302-3C>G; c.4185G>A and c.4675+1G>A) and six splice-site variants in BRCA2 (c.475G>A; c.476-2>G; c.7007G>A; c.8755-1G>A; c.9117+2T>A and c.9118-2A>G) were demonstrated to result in aberrant transcripts and are considered as deleterious mutations. Conclusion This study represents an evaluation of deleterious genetic variants in the BRCA1 and 2 genes in the Czech population. The classification of several splice-site variants as true pathogenic mutations may prove useful for genetic counselling of families with high risk of breast and ovarian cancer.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1471-2407
Relation: http://www.biomedcentral.com/1471-2407/8/140; https://doaj.org/toc/1471-2407
DOI: 10.1186/1471-2407-8-140
URL الوصول: https://doaj.org/article/62d840e855f94cc688742f792dce4cdb
رقم الانضمام: edsdoj.62d840e855f94cc688742f792dce4cdb
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:14712407
DOI:10.1186/1471-2407-8-140